In an interview, Kanish Malik, President, Operations, Glenmark Pharmaceuticals, with Chemical Today Magazine talks in depth about the revolutionary journey that the pharmaceutical industry is in today.
By Shivani Mody
Trends and developments in generic formulations, APIs.
Generics still drive the global pharma growth while representing a volume majority (~55 percent). There has been a tremendous rise in competition in the generics space as blockbusters come off the patent protection. There are multiple other factors at play such as evolving expectations from the regulatory bodies, renewed focus on patient safety, government’s policies to bring the prices down, and approval timelines getting shorter. These are going to test the core ability and speed of all the generic suppliers to provide cost-effective solutions while ensuring that patient safety remains the first and foremost priority.
In addition, the consolidation of trade is redefining the service expectations demanding an upfront commitment on first-time-right capabilities from supply chain with a manufacturing focus.
Focal areas - pharma industry, for business enhancement.
Optimizing the drug life cycle is enhancing the traditional value creation that was largely dependent on intellectual property backed by patents. This optimization would mean expanding the time horizon to realize the overall potential.
Organizations need to be nimble-footed about the development basket. The need for speed, robustness, and first-time-right capabilities that would lead to breaking the fully integrated pharma chain into centers of excellence and a rigour in selecting partners to enable product pipeline.
Read More: A pill of paradigm change
No comments:
Post a Comment